EFPIA - NEWSLETTER

EFPIA Newsletter 30 May 2024

#Imagine if all Europeans had access to new medicines on day one after authorisation

Hear more from Stefan Oelrich, Vice-President of EFPIA and Member of the Board of Management of Bayer AG and Head of its Pharmaceuticals Division.

Read more here.

Blog

28 May 2024 New data demonstrates the value of regulatory data protection (RDP), and its impact on European...

EFPIA believes EU leaders’ focus on competitiveness is positive but more joined-up thinking is urgently needed to achieve...

Access Gap - How to bridge the gap?

Watch the recording of Nathalie Moll's speech at the 3rd INFARMA Conference 'Access Gap - How to Bridge the Gap?' held in Warsaw.

Nathalie presented EFPIA's view on key EU files such as the Pharmaceutical Legislation and HTA, and voiced her readiness to work together with the future Polish Presidency of the Council of the European Union to create the right innovation ecosystem for Europe and Poland.

Events

31 MAY 2024

IMI impact on antimicrobial resistance Online event

Combatting antimicrobial resistance: the legacy of the IMI COMBACTE projects.

Learn more →

04 JUN 2024

Countdown to the EU HTA: how can we seize this opportunity to improve patient access... Online session

In January 2025, all new cancer medicines and advanced therapy medicinal products (ATMPs) will be jointly assessed at...

Learn more →

What we are reading

EU Clinical Trials Discussion Platform Sets Off With Collaborative Tone 29 May 2024 (Pink Sheet)

Crossing the bridge – from project to non-profit 28 May 2024 (Innovative Health Initiative)

Belgium developing new class of antibiotics, but incentives and market support needed 28 May 2024 (Euractiv)

About the EFPIA newsletter

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 37 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.

Tel: +32 (0)2 626 25 55
Communications@efpia.eu

▶